The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Burden of disease and costs of exposure to endocrine disrupting chemicals in the European Union: an updated analysis
Open accessAbstract
Summary: A previous report documented that endocrine disrupting chemicals contribute substantially to certain forms of disease and disability. In the present analysis, our main objective was to update a range of health and economic costs that can be reasonably attributed to endocrine disrupting chemical exposures in the European Union, leveraging new burden and disease cost estimates of female reproductive conditions from accompanying report. Expert panels evaluated the epidemiologic evidence, using adapted criteria from the WHO Grading of Recommendations Assessment, Development and Evaluation Working Group, and evaluated laboratory and animal evidence of endocrine disruption using definitions recently promulgated by the Danish Environmental Protection Agency. The Delphi method was used to make decisions on the strength of the data. Expert panels consensus was achieved for probable (>20%) endocrine disrupting chemical causation for IQ loss and associated intellectual disability; autism; attention deficit hyperactivity disorder; endometriosis; fibroids; childhood obesity; adult obesity; adult diabetes; cryptorchidism; male infertility, and mortality associated with reduced testosterone. Accounting for probability of causation, and using the midpoint of each range for probability of causation, Monte Carlo simulations produced a median annual cost of €163 billion (1.28% of EU Gross Domestic Product) across 1000 simulations. We conclude that endocrine disrupting chemical exposures in the EU are likely to contribute substantially to disease and dysfunction across the life course with costs in the hundreds of billions of Euros per year. These estimates represent only those endocrine disrupting chemicals with the highest probability of causation; a broader analysis would have produced greater estimates of burden of disease and costs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The value of a statistical life: A critical review of market estimates throughout the world
Viscusi, W. K., & Aldy, J. E. (2003) · Journal of Risk and Uncertainty · doi:10.1023/a:1025598106257 · Cited by 2,135
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Cost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Atkins, D., Eccles, M., Flottorp, S., Guyatt, G. H., Henry, D., Hill, S., Liberati, A., O'Connell, D., Oxman, A. D., Phillips, B., et al. (2004) · BMC Health Services Research · doi:10.1186/1472-6963-4-38 · Cited by 1,235 · cited 3×
“, 2012) and GRADE Working Group (Atkins et al., 2004; Schunemann et al., 2008) were applied to assess strength of evidence, and the strength of the literature was used to assess a probability that the disease costs estimated through the IOM approach are causally related to EDCs.”
Method
Cited by
Endocrine-disrupting chemicals: Implications for human health
Kahn, L. G., Philippat, C., Nakayama, S. F., Slama, R., & Trasande, L. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30129-7 · Cited by 797
Self-citationBarratt, C. L. R., Björndahl, L., De Jonge, C. J., Lamb, D. J., Osorio Martini, F., McLachlan, R., Oates, R. D., van der Poel, S., St John, B., Sigman, M., et al. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx021 · Cited by 505
“In this field strong scientific, socio-economic healthcare and political arguments have consistently been marshalled to support research into what has been termed an ‘epidemic’ of male reproductive health problems (Hauser et al., 2015; Skakkebaek et al., 2016; Trasande et al., 2016).”
BackgroundEndocrine Disrupting Chemicals: Effects on Endocrine Glands
Lauretta, R., Sansone, A., Sansone, M., Romanelli, F., & Appetecchia, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00178 · Cited by 340
Bonde, J. P., Flachs, E. M., Rimborg, S., Glazer, C. H., Giwercman, A., Ramlau-Hansen, C. H., Hougaard, K. S., Høyer, B. B., Hærvig, K. K., Petersen, S. B., et al. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw036 · Cited by 304
Attina, T. M., Hauser, R., Sathyanarayana, S., Hunt, P. A., Bourguignon, J.-P., Myers, J. P., DiGangi, J., Zoeller, R. T., & Trasande, L. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30275-3 · Cited by 297
Self-citationEndocrine-disrupting chemicals: economic, regulatory, and policy implications
Kassotis, C. D., Vandenberg, L. N., Demeneix, B. A., Porta, M., Slama, R., & Trasande, L. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30128-5 · Cited by 273
Self-citationYan, D., Jiao, Y., Yan, H., Liu, T., Yan, H., & Yuan, J. (2022) · Environmental Health · doi:10.1186/s12940-022-00858-8 · Cited by 104
Praegnatio Perturbatio—Impact of Endocrine-Disrupting Chemicals
Padmanabhan, V., Song, W., & Puttabyatappa, M. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa035 · Cited by 103
Metadata
- Authors
- Trasande, L., Zoeller, R. T., Hass, U., Kortenkamp, A., Grandjean, P., Myers, J. P., DiGangi, J., Hunt, P. M., Rudel, R., Sathyanarayana, S., Bellanger, M., Hauser, R., Legler, J., Skakkebaek, N. E., & Heindel, J. J.
- Venue
- Andrology
- Publisher
- Wiley
- Published
- 2016-03-22
- Volume
- 4
- Issue
- 4
- Pages
- 565-572
- ISSN
- 2047-2919 (ISSN-L)
- 2047-2927
- OpenAlex
- W2308918641
- Cited by
- 184
- References
- 4
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.